Get started
Author

Mihaëla Achille

Observed names: Mihaela ACHILLE, Mihaela Achille
OpenAlex ID: A5111616120
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2022 · François-Clément Bidard, François-Clément Bidard, et al. · The Lancet Oncology · 350
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · T. Bachelot, E. Ciruelos, et al. · Annals of Oncology · 114
PDF
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
2022 · François-Clément Bidard, Anne-Claire Hardy-Bessard, et al. · Cancer Research · 31
Response to Erlotinib in First-Line Treatment of Non–Small-Cell Lung Cancer in a White Male Smoker with Squamous-Cell Histology
2006 · Mihaela Achille, Marielle Gallegos-Ruiz, et al. · Clinical Lung Cancer · 12
Expression of Cell Cycle Biomarkers and Telomere Length in Papillary Thyroid Carcinoma: A Comparative Study Between Radiation-Associated and Spontaneous Cancers
2009 · Mihaela Achille, Houda Boukheris, et al. · American Journal of Clinical Oncology · 9
Abstract P1-18-16: First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial
2022 · Suzette Delaloge, Anne-Claire Hardy-Bessard, et al. · Cancer Research · 2
Works count: 6
Citation count: 518
H-index: 5
I10-index: 4
Year
Topic
Type